3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
9
Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Obesity
3
Breast Neoplasms
3
Brain Neoplasms
3
Sarcopenia
2
Multiple Myeloma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Renal Insufficiency, Chronic
1
Rehabilitation Exercise
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphedema
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Resistance Training
×
1 year
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled